GO:0034673 inhibin-betaglycan-ActRII complex

The inhibin-betaglycan-ActRII complex (GO:0034673) is a membrane-associated protein assembly that negatively regulates activin B, a member of the TGF-beta superfamily. This complex is essential for controlling activin signaling, which influences diverse processes such as cell proliferation, differentiation, and hormone regulation. Researchers study this complex to understand how cells balance growth and differentiation signals, and how its dysregulation contributes to diseases including reproductive disorders and cancer. The complex is composed of three key proteins: inhibin, betaglycan (also known as type III TGF-beta receptor), and the type II activin receptor ActRII. Inhibin binds to betaglycan, which in turn presents inhibin to ActRII, forming a ternary complex that prevents activin from activating the receptor. This mechanism is a prime example of how co-receptors can modulate ligand-receptor interactions in the TGF-beta superfamily.

GO:0034673 is a cellular component term describing a protein complex that consists of inhibin, type III transforming growth factor beta receptor (betaglycan), and the type II activin receptor ActRII. The complex is thought to negatively regulate the activity of activin B.

The inhibin-betaglycan-ActRII complex is important because it provides a critical checkpoint for activin B signaling, which controls a wide range of biological functions including reproduction, development, and tissue homeostasis. Dysregulation of this complex can lead to uncontrolled activin signaling, contributing to diseases such as cancer and reproductive disorders. Understanding its assembly and regulation offers potential therapeutic targets for modulating TGF-beta superfamily pathways.

The key genes and proteins involved in the inhibin-betaglycan-ActRII complex include the ligands, receptors, and co-receptors that constitute or regulate this assembly.

The formation and activity of the inhibin-betaglycan-ActRII complex are regulated at multiple levels. Expression of betaglycan (TGFBR3) and ActRII is controlled by hormones and growth factors, including FSH and TGF-beta itself. Additionally, post-translational modifications such as glycosylation of betaglycan can influence its affinity for inhibin. The complex is also subject to feedback regulation by downstream signaling molecules, ensuring tight control of activin B activity.

Dysregulation of the inhibin-betaglycan-ActRII complex has been implicated in reproductive disorders such as premature ovarian failure and male infertility. Mutations in TGFBR3 or ACVR2A can disrupt complex formation, leading to altered activin signaling and impaired gametogenesis.

Altered expression of betaglycan and ActRII is observed in various cancers, including ovarian, prostate, and breast cancer. Loss of betaglycan can enhance activin signaling, promoting tumor growth and metastasis. Targeting the complex may offer therapeutic opportunities.

Activin signaling, regulated by this complex, influences muscle mass and bone density. Disruption of the complex may contribute to conditions such as sarcopenia and osteoporosis.

CRISPR-Cas9 knockout of TGFBR3, ACVR2A, or INHBA allows researchers to study the loss of complex components and its effects on activin signaling. This method is ideal for identifying the specific contributions of each protein.

Co-immunoprecipitation followed by mass spectrometry can identify interacting partners and confirm the assembly of the inhibin-betaglycan-ActRII complex. This approach reveals dynamic changes in complex composition under different conditions.

RNA sequencing after perturbation of the complex provides a global view of downstream transcriptional changes, identifying activin target genes and pathways. This method helps link the complex to specific biological processes.

Fluorescent tagging of complex components enables real-time visualization of assembly, trafficking, and interactions at the cell membrane. This technique is valuable for understanding spatiotemporal dynamics.

Researchers studying inhibin-betaglycan-ActRII complex-related genes often need to determine whether a candidate gene is causally involved in complex assembly, signaling, or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research.

The inhibin-betaglycan-ActRII complex (GO:0034673) is a critical regulator of activin B signaling, with profound implications for reproduction, development, and disease. Understanding its assembly and function provides insights into TGF-beta superfamily control and offers potential therapeutic avenues. EDITGENE's CRISPR services empower researchers to dissect this complex with precision and speed.